Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Kirsten Messick"'
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 49(7)
Clinical induction liability is assessed with human hepatocytes. However, underpredictions in the magnitude of clinical induction have been reported. Unfortunately, in vivo studies in animals do not provide additional insight because of species diffe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::85293219366bb4ff24982fe390e86a7a
https://pubmed.ncbi.nlm.nih.gov/33863817
https://pubmed.ncbi.nlm.nih.gov/33863817
Autor:
Yi-Chen Chen, Kirsten Messick, Justin Ly, Xiaolin Zhang, Eugene Chen, Jonathan Cheong, Jae H. Chang
Publikováno v:
Xenobiotica. 49:602-610
1. Oatp inhibitors have been shown to significantly increase the plasma exposure of statins. However, understanding alterations of liver concentration is also important. While modeling has simulated liver concentration changes, availability of experi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ec41ce2b8b6f499d2dd07c32092add
https://doi.org/10.1080/00498254.2018.1478167
https://doi.org/10.1080/00498254.2018.1478167
Autor:
Roxanne Andaya, Kirsten Messick, Jacqueline M. Tarrant, Xiao Ding, Trung Nguyen, Jessica Couch, Michelle G. Schweiger, Shelly Zhong, Xiaorong Liang, Bianca M. Liederer, Brian Dean, Eric Harstad
Publikováno v:
ILAR Journal. 57:157-165
Improved small molecule bioanalytical sensitivity and concomitant decreased sample volume requirements provide an opportunity to reconsider how toxicokinetic (TK) data are collected in rat toxicity studies. Often, satellite groups of rats are designa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::170e3011bdf3e000ee702420889a31da
https://doi.org/10.1093/ilar/ilw023
https://doi.org/10.1093/ilar/ilw023
Publikováno v:
Drug Metabolism and Disposition. :DMD-AR
Clinical induction liability is assessed with human hepatocytes. However, underpredictions in the magnitude of clinical induction have been reported. Unfortunately, in vivo studies in animals do not provide additional insight because of species diffe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9ec5aeca3effb40be3e81c997180de8
https://doi.org/10.1124/dmd.121.000439
https://doi.org/10.1124/dmd.121.000439
Publikováno v:
Drug Metabolism and Disposition. 44:1736-1741
Animals are not commonly used to assess drug-drug interactions due to poor clinical translatability arising from species differences that may exist in drug-metabolizing enzymes and transporters, and their regulation pathways. In this study, a transge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::837dc7172f9f0a56b382a796a282285e
https://doi.org/10.1124/dmd.116.072132
https://doi.org/10.1124/dmd.116.072132
Autor:
Cristine Quiason, Lulu Yang, Edna F. Choo, Justin Ly, Sheerin K. Shahidi-Latham, Jocelyn Chan, Kirsten Messick, Emile Plise
Publikováno v:
Molecular Pharmaceutics. 11:4199-4207
Cobimetinib is a MEK inhibitor currently in clinical trials as an anticancer agent. The objectives of this study were to determine in vitro and in vivo if cobimetinib is a substrate of P-glycoprotein (P-gp) and/or breast cancer resistance protein (Bc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51ed8c5ab0b2bfed0393302126bbf91f
https://doi.org/10.1021/mp500435s
https://doi.org/10.1021/mp500435s
Autor:
Yuzhong Deng, Cornelis E. C. A. Hop, Lulu Yang, Xiaorong Liang, Mark Zak, Kirsten Messick, Shuguang Ma, Ann R Qin, Peter S. Dragovich, Justin Ly, Bianca M. Liederer, Brian Dean
Publikováno v:
Bioanalysis. 6:1445-1457
Background: NAD+is an endogenous analyte and is unstable during blood sample collection, both of which present obstacles for quantitation. Moreover, current procedures for NAD+sample collection require onsite treatment with strong acid to stabilize t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d447efcf8e90aa3c7cd1f5aaccf9a01c
https://doi.org/10.4155/bio.14.8
https://doi.org/10.4155/bio.14.8
Autor:
Ryan H. Takahashi, Kirsten Messick, Wei Jia, Cornelis E. C. A. Hop, Jacob Z. Chen, Teresa Mulder, Harvey Wong, Joseph P. Lyssikatos, Qin Yue, S. Cyrus Khojasteh, Shuguang Ma, Justin Ly, Georgette Castanedo, Lichuan Liu
Publikováno v:
Drug Metabolism and Disposition. 42:343-351
Vismodegib (Erivedge, GDC-0449) is a first-in-class, orally administered small-molecule Hedgehog pathway inhibitor that is approved for the treatment of advanced basal cell carcinoma. Previously, we reported results from preclinical and clinical radi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7426576dde36048e6cf0d9f17f3619ff
https://doi.org/10.1124/dmd.113.055715
https://doi.org/10.1124/dmd.113.055715
Autor:
M. Allan Jaochico, Jacob Z. Chen, Joachim Rudolf, Teresa Mulder, S. Cyrus Khojasteh, Peter W. Fan, Kirsten Messick, Robert T. Cass, Lesley J. Murray, Wendy Lee, Shannon Liu, Matthew Wright, Matthew R. Durk, Nicole Valle, Hank La, James J. Crawford, Ning Liu
Publikováno v:
Drug Metabolism Letters
Background: Significant under-prediction of in vivo clearance in rat was observed for a potent p21-activated kinase (PAK1) inhibitor, GNE1. Objective: Rate-determining (rapid uptake) and rate-limiting (slow excretion) steps in systemic clearance and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3cd6e0f5d3f0cd10fd2e22896eb4e47
https://pubmed.ncbi.nlm.nih.gov/27063863
https://pubmed.ncbi.nlm.nih.gov/27063863
Publikováno v:
Drug Metabolism and Pharmacokinetics. 33:S47
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d81db78db313197a54ddb1028ae6bb7
https://doi.org/10.1016/j.dmpk.2017.11.164
https://doi.org/10.1016/j.dmpk.2017.11.164